Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study.
Thirty-four patients suffering from rhinoconjunctivitis with or without asthma due to grass pollen, were submitted to sublingual immunotherapy according to a double blind placebo controlled experimental plan; eighteen patients received the active therapy, sixteen the placebo. A rush preseasonal treatment schedule was followed in order to reach the maintenance dose in 15 days with two administrations per day; the top dose reached was then administered three times a week until the end of the pollen season. The symptoms and drugs related to rhinoconjunctivitis and asthma were recorded by means of diary cards and grass pollen counts were performed during the season. The actively treated group showed a reduction of symptoms of rhinoconjunctivitis and asthma and a lower intake of drugs for the same symptoms; all these differences resulted to be statistically significant. No patient showed local or systemic side effects of any relevance. According to these results of our study, sublingual rush immunotherapy is clinically effective and because of the ease of handling, the shortness of the treatment, the absence of relevant side effects and the high compliance of the patient can be considered as an alternative to classic injective immunotherapy in grass pollen allergic patients.
Feliziani
V
V
Ambulatorio di Allergologia Divisione Medicina, Ospedale Civile di Lanciano, Chieti, Italia.
Lattuada
G
G
Parmiani
S
S
Dall'Aglio
P P
PP
D000286:Administration, Sublingual; D000485:Allergens; D003233:Conjunctivitis, Allergic / Q000276:immunology / Q000628:therapy*; D004311:Double-Blind Method; D006801:Humans; D007167:Immunotherapy; D010936:Plant Extracts / Q000627:therapeutic use; D006109:Poaceae; D011058:Pollen; D006255:Rhinitis, Allergic, Seasonal / Q000276:immunology / Q000628:therapy*; D013997:Time Factors
D000485:Allergens; D010936:Plant Extracts